

Axinn IP Update: Hikma Pharmaceuticals USA, Inc. v. Vanda Pharmaceuticals, Inc.

A photograph of a modern building's curved glass facade, showing multiple stories of windows reflecting the sky. The building is on the right side of the page, and the background is a light blue gradient.

PUBLICATIONS | 1 MIN READ


March 18, 2019

By: Thomas K. Hedemann

Axinn Update

Today the Supreme Court took the relatively uncommon step of calling for the views of the solicitor general as to the petition for certiorari in *Hikma Pharmaceuticals USA, Inc. v. Vanda Pharmaceuticals, Inc.*, Docket No. 18-817. Whereas the Court grants certiorari to only about one percent of petitions generally, it grants around one third of the petitions for which it has called for the views of the solicitor general. If the Court grants certiorari here, it will address the question “[w]hether patents that claim a method of medically treating a patient automatically satisfy Section 101 of the Patent Act, even if they apply a natural law using only routine and conventional steps.” The petition was an appeal from a decision by a split Federal Circuit panel that a method for treating a patient with schizophrenia, which involved analyzing the patient’s DNA and adjusting the dosage of a drug accordingly, was patent eligible because it was not directed to a law of nature under step one of the *Mayo/Alice* two-step subject matter eligibility test. *Vanda Pharmaceuticals, Inc. v. West-Ward Pharmaceuticals International Limited*, 887 F.3d 1117, 1133-36 (Fed. Cir. 2018). Any decision could have a significant impact on patents directed to methods of treatment in the pharmaceutical and biologics industries.

Related People



Thomas K. Hedemann

Related Services

Intellectual Property

To subscribe to our publications, [click here](#).

Featured Insights

- American Bar Association 2025 Asia-Pacific Conference
SPEAKING ENGAGEMENT ANTITRUST
- NBA Commercial Law Section 38th Annual Corporate Counsel Conference
SPONSORSHIP ANTITRUST
- GCR Live: Law Leaders Global 2025
SPEAKING ENGAGEMENT ANTITRUST
- The 32nd Annual Marketing Partner Forum
EVENT
- SABA North America Corporate Counsel Retreat 2025
SPONSORSHIP ANTITRUST
- Axinn Antitrust Insight: FTC Announces Revised HSR Thresholds for 2025
CLIENT ALERTS ANTITRUST
- Four Axinn Thought Leadership Pieces Nominated for the Antitrust Writing Awards
AWARDS & RECOGNITIONS ANTITRUST

- Merger Remedies Back in Vogue Under Trump

MEDIA MENTIONS ANTITRUST

- Three Takeaways from the Initial Determination at the ITC Regarding Standard Essential Patents in the 1380 Investigation

AXINN VIEWPOINTS INTELLECTUAL PROPERTY

- A POSA's Motivation Is Not Required To Be the Same as the Inventor's in Evaluating Obviousness

AXINN VIEWPOINTS INTELLECTUAL PROPERTY

© 2025 Axinn, Veltrop & Harkrider LLP. All Rights Reserved